Therapeutic doses of efzofitimod demonstrate efficacy in pulmonary sarcoidosis.

Slopes analysis also showed that FEV 1 increased in the Therapeutic group, but decreased in the Subtherapeutic group, over the course of the trial, although the trend did not reach statistical significance (p=0.196; figure 4 and table 2 ).

also in 111,027 other papers

Our analysis shows a highly significant reduction in relapses after OCS taper in the Therapeutic group (7.7%) compared to the Subtherapeutic group (54.4%) and a markedly longer time-to-first-relapse in the Therapeutic group ( figure 2 , table 2 ).

also in 132,142 other papers